Project
BMS CA224-104 Relatilimab
Ongoing - recruitment closed · 2021 until 2099
Weindler Susanne, Demmer-Steingruber Ruth, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2021
End Date
2099
Financing
Industry
Labels
lung cancer
Brief description/objective
BMS CA224-104 Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)